Current Report Filing (8-k)
September 13 2021 - 08:02AM
Edgar (US Regulatory)
0001535955
false
0001535955
2021-09-13
2021-09-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported):
September
13, 2021
LIPOCINE
INC.
(Exact
name of registrant as specified in its charter)
Commission
File No. 001-36357
Delaware
|
|
99-0370688
|
(State or other jurisdiction
of incorporation)
|
|
(IRS Employer
Identification Number)
|
675
Arapeen Drive, Suite 202
Salt
Lake City, Utah 84108
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (801) 994-7383
Former
name or former address, if changed since last report: Not Applicable
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
I
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.0001 per share
|
|
LPCN
|
|
The
NASDAQ Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §
230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01 Other Events
The
Company has updated its corporate presentation that it uses when meeting with investors, analysts and others. The presentation is filed
as Exhibit 99.1.
Item
9.01 Financial Statements and Exhibits.
The
following exhibits are filed with this report:
Exhibit
No.
|
|
Description
|
99.1
|
|
Corporate Presentation
|
104
|
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
LIPOCINE INC.
|
|
|
|
|
|
Date:
|
September
13, 2021
|
|
By:
|
/s/
Mahesh V. Patel
|
|
|
|
|
Mahesh
V. Patel
|
|
|
|
|
President
and Chief Executive Officer
|
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Mar 2023 to Mar 2024